Advancing CNTY-813 as a potential functional cure in Type 1 DiabetesCNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo ...

("Eledon") (NASDAQ: ELDN) today announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free ...

All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to ...

There's new hope for a functional cure for Type 1 diabetes. Just the idea of waking up and having a perfect blood sugar and ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant ...

Type 1 diabetes (T1D) is a lifelong autoimmune disorder where the immune system attacks islets, certain areas of the pancreas ...

Type 1 diabetes (T1D) is a lifelong autoimmune disorder where the immune system attacks islets, certain areas of the pancreas ...

Type 1 diabetes (T1D) is a lifelong autoimmune disorder where the immune system attacks islets, certain areas of the pancreas, and destroys cells that ...

KYOTO—Kyoto University Hospital officials announced on April 14 that a research team conducted a clinical trial in ...

On May 27, 2026, NewcelX Ltd. announced it has submitted a Pre-IND briefing package to the U.S. FDA to support a proposed first-in-human clinical trial of NCEL-101 for Type 1 Diabetes, in combination ...

Cheryl Pile met the criteria for an islet-cell transplant program in Alberta to treat her debilitating diabetes. But it took three specialists to finally get her referred to the program. Pile was ...

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: ...